Current status and prospects of using the prokinetic acotiamide in gastroenterology: A review
| Autor: | Igor V. Maev, Dmitry N. Andreev, Andrew V. Zaborovsky, Elena G. Lobanova |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Терапевтический архив, Vol 95, Iss 8, Pp 716-721 (2023) |
| Druh dokumentu: | article |
| ISSN: | 0040-3660 2309-5342 00403660 |
| DOI: | 10.26442/00403660.2023.08.202396 |
| Popis: | Acotiamide is a prokinetic with a novel mechanism of action an antagonist of muscarinic M1 and M2 receptors and an acetylcholinesterase inhibitor. Acetylcholine is the central mediator of the tone of the muscular components of the gastrointestinal tract, increasing its motor activity. Blockade of presynaptic M1 and M2 receptors neutralizes the inhibitory effect of the feedback mechanism on the acetylcholine synthesis, while inhibition of acetylcholinesterase in the synaptic cleft reduces the acetylcholine degradation. Currently, the clinical efficacy of acotiamide in the population of patients with functional dyspepsia is demonstrated in more than 10 clinical studies in different regions of the world, demonstrating a reduction of the symptoms of the disease during treatment with this agent and an improvement in the quality of life of patients. In addition, the combination of acotiamide with proton pump inhibitors optimizes the management of patients with gastroesophageal reflux disease. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|